Skip to main content
editorial
. 2019 Dec;8(Suppl 6):S585–S588. doi: 10.21037/tcr.2019.06.39

Table 1. FDA approval timeline for first line renal cell carcinoma.

Favorable risk Intermediate/poor risk
High dose interleukin 2 [1992] High dose interleukin 2 [1992]
Sunitinib [2006] Sunitinib [2006]
Bevacizumab + interferon alfa [2009] Temsirolimus [2007]
Pazopanib [2009] Bevacizumab + interferon alfa [2009]
Axitinib + pembrolizumab [2019] Pazopanib [2009]
Axitinib + avelumab [2019] Carbozantinib [2016]
Ipilimumab + nivolumab [2018]
Axitinib + pembrolizumab [2019]
Axitinib + avelumab [2019]